Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US

Objective: To estimate the budget impact of avelumab as a treatment option for patients with treatment-naïve first-line (1L) and previously treated second-line or later (2L+) metastatic Merkel cell carcinoma (mMCC) in the US. Methods: A budget impact model was developed to evaluate the addition of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bharmal, Murtuza, Kearney, Mairead, Zheng, Ying, Phatak, Hemant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535410/
https://www.ncbi.nlm.nih.gov/pubmed/31190927
http://dx.doi.org/10.2147/CEOR.S202642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535410/
https://www.ncbi.nlm.nih.gov/pubmed/31190927
http://dx.doi.org/10.2147/CEOR.S202642

Ejemplares similares